Purpose The incidence of osteoporosis-related fractures will increase substantially over the coming decades as the population ages globally. This has important economic and public health implications, contributing substantially to morbidity and excess mortality in this population. Methods When prescribing for older patients the effectiveness profile of drugs needs to be balanced against their tolerability in individual patients. Results Currently we have good anti-fracture data to support the use of many available anti-resorptive and anabolic drugs including bisphosphonates, strontium ranelate and recombinant human parathyroid hormone. We also have evidence to demonstrate the importance of calcium and vitamin D repletion in these patients. However, in recent years our understanding of normal bone physiology and the mechanisms underlying the development of osteoporosis has significantly advanced and this has led to the development of new therapies. Novel agents, particularly denosumab, but also inhibitors of cathepsin K and anabolic agents that act on Wnt signalling, will increase the therapeutic options for clinicians in the coming years.
Introduction
Osteoporosis is a metabolic bone disease that results in bone fragility and increased susceptibility to fracture. As populations age globally, the incidence of osteoporosisrelated fractures will rise substantially over the coming decades. Even if age-adjusted incidence rates remain stable, the estimated number of hip fractures worldwide will rise from 1.7 million in 1990 to 6.3 million in 2050 [1] . Approximately 1 in 2 women and 1 in 4 men aged over 50 years will have an osteoporosis-related fracture in their lifetime. The increase in medical visits, hospitalisations, need for community support and nursing home admissions will pose a major economic burden on healthcare systems. Currently, the combined annual cost of all osteoporotic fractures has been estimated at $20 billion for the US and $30 billion for the EU [2] .
In order to offer patients greater protection against osteoporosis-related fractures an increasing number of newer therapies have been developed. Knowledge of underlying mechanisms of osteoporosis has advanced in recent years allowing novel agents to be introduced ( Fig. 1) . Bone is continually remodelled to replace microdamage and to adapt bone density to patterns of usage. Age-related bone loss results in 0.5% decline in bone mass per year. This occurs because of an imbalance between the activity of osteoclasts (bone-resorbing cells) and osteoblasts (bone-forming cells) and multiple factors are now known to regulate this balance. In this article we summarise the evidence of established treatments before outlining a number of newer agents and prescribing considerations for this common condition.
Determining fracture risk
Prevention of osteoporosis is preferable to treatment as microarchitectural changes associated with bone loss are largely irreversible. Although BMD is the best available non-invasive assessment of bone strength, other factors contribute to bone quality including the mineralisation and rate of bone turnover [3] . Markers of bone formation, turnover and resorption have been used in some trials to assess drug efficacy. Studies also show their highly significant correlation with subsequent rate of bone loss and future fracture risk [4] and subgroups with high turnover at baseline have been shown in some studies to gain most from antiresorptive therapy [5] [6] [7] .
Pharmacological treatments may stabilise or increase BMD, but are unlikely to fully restore bone quality and strength. Dual energy X-ray absorptiometry (DXA) is the most widely used method for measuring BMD as it gives very precise measurements at clinically relevant sites. The greatest relative risk of fracture is in individuals with lower BMD, but the absolute number of fractures in those with BMD T-scores in the osteopenic range is greater than those with T-scores in the osteoporotic range. Therefore, assessment of risk factors that are independent of BMD is important for fracture prediction [8] . Advanced age and previous fracture are the most significant of these validated (Table 1) . In 2008 the World Health Organisation (WHO) introduced FRAX®, the Fracture Risk Assessment Tool, which estimates the 10-year probability of hip fracture or major osteoporotic fractures combined [9] . It has been validated in 11 independent cohorts and allows estimation of 10-year fracture probability from an individual's set of risk factors alone or in combination with BMD. Patients can be stratified according to fracture risk instead of using BMD alone and intervention can therefore be effectively targeted to those at highest risk of fracture (Fig. 2) . The FRAX® tool enables the estimation of risk based on a wider range of risk factors, and treatment efficacy is dependent on the level of risk in the population analysed. Furthermore, thresholds for cost-effective pharmacological intervention have been calculated using fracture and economic data that are country-specific [10] . FRAX® can also be used to assess the cost-effectiveness of individual drugs to treat osteoporosis [11, 12] .
Since the introduction of FRAX®, two new fracture clinical risk scores (QFractureScores) have been developed and validated in the UK [13] . In addition to traditional variables already included in the FRAX® algorithm, further fracture risk factors are included, such as history of falls, type 2 diabetes, cardiovascular disease, asthma, use of hormone replacement therapy (HRT) and use of tricyclic antidepressants. No BMD score is used in the calculation and patients as young as 30 can be assessed. It can be used to estimate fracture risk at 1, 2, 5 and 10 years. Validation statistics, especially for the hip fracture algorithm, suggest that the QFractureScores are likely to be effective at identifying patients at high risk of fracture and suggested favourable performance compared with FRAX®.
Application of this approach to fracture risk assessment to individual patients allows clinicians to make more informed decisions when considering whether or not to commence pharmacological intervention.
Anti-resorptive agents
Calcium and vitamin D Calcium and vitamin D are necessary for normal skeletal homeostasis and are considered the first step in osteoporosis treatment. Inadequate intake of calcium and vitamin D leads to reduced calcium absorption, a compensatory rise in parathyroid hormone, higher bone remodelling rates and increased bone loss. Vitamin D deficiency is also linked to reduced muscle function and increased risk of falling, and its replacement has been shown to reduce the rate of falling amongst older individuals [14] . The positive association between calcium and vitamin D levels and bone mineral density (BMD) has been well documented [15] [16] [17] . However, their replacement, either alone or in combination, has been shown to lower fracture rates in some trials, but not in others. Calcium supplementation alone has been shown to reduce the incidence of osteoporotic fracture compared with placebo (HR 0.66) only in patients who are over 80% compliant [18] .
The relationship between vitamin D replacement and fracture prevention is unclear when first examined and many studies using various doses of 25OHD and differently aged study populations have attempted to clarify this relationship. Despite some inconsistent trial results it appears that vitamin D supplementation studies that had positive results achieved higher vitamin D levels. From the available evidence, it seems that individuals will benefit by having their 25OHD levels no lower than 70 nmol/l. Vitamin D protects against fracture by decreasing PTH and increasing bone mass and also by lowering the risk of falling [19] . A higher level may provide additional benefit, but this has not been established. Supplemental calcium, used in many of the trials, both positive and negative, may be essential for benefit, but this remains uncertain. The recommended dose of calcium, usually in the form of calcium carbonate, is 1 g daily and common side effects include dyspepsia and constipation. However, an increased risk of myocardial infarction (HR 1.31, 95% CI 1.02 to 1.67) in patients on calcium supplements, without coprescribed vitamin D, was recently reported in a metaanalysis by Bolland and colleagues [20] , which raises concerns about its widespread use. Because of the limited evidence available of its benefit when used alone, it is advised that calcium should not be prescribed to patients with osteoporosis unless they are also receiving vitamin D and/or an effective treatment for osteoporosis.
Bisphosphonates
Bisphosphonates are now widely used in the treatment of osteoporosis as they inhibit bone resorption with relatively few side effects. There are two classes of bisphosphonate: the nitrogen-containing and non nitrogen-containing bisphosphonates, all of which have a structure similar to pyrophosphate and thereby inhibit the activation of enzymes that utilise pyrophosphate [21] Although oral bisphosphonates are well tolerated if swallowed as indicated (Table 2) , caution is advised with a background of gastrointestinal complaints. Recent reports have proposed a link between bisphosphonate-related oesophagitis and oesophageal cancer [31] and this association has been investigated using data from the UK General Practice Research database and reported in two separate studies. At a follow-up period of 4.5 years, Cardwell et al. reported no increase in the risk of oesophageal or gastric cancer with bisphosphonate use [32] . In contrast, the case-control analysis by Green et al.
[33] found an increase in the risk of oesophageal cancer with 10 or more prescriptions for oral bisphosphonates and with prescriptions over a 5-year period (an increase in incidence of 1 per 1,000 to 2 per 1,000 population aged 60-79 years with 5 years' use of oral bisphosphonates). This study had a longer follow-up period of 7.7 years. However, neither study validated diagnoses by medical records nor provided information on whether drugs were taken according to directions. Even if oral bisphosphonates do increase the risk of oesophageal cancer, the incidence in the population would be expected to remain relatively low. As evidence to date is inconclusive, cautious prescribing of bisphosphonates, patient education and active follow-up are advised. Adverse skeletal events in the form of atypical fragility fractures and osteonecrosis of the jaw in patients on bisphosphonates have been described, but remain relatively rare. It is plausible that atypical fragility fractures could follow from suppression of bone remodelling, but highquality studies proving causality are lacking. A recent secondary analysis of three large bisphosphonate trials found no significant increase in the risk of atypical fracture associated with bisphosphonate use for up to 10 years [34]. However, the study was not adequately powered for definitive conclusions. A further British cohort study using national healthcare data found alendronate-treated patients to be at higher risk of hip and subtrochanteric/diaphyseal fracture than matched control subjects [35] . Large cumulative doses of alendronate were not, however, associated with a greater absolute risk of subtrochanteric/diaphyseal fractures than small cumulative doses, suggesting that these fractures could be due to osteoporosis rather than to alendronate.
Osteonecrosis of the jaw (ONJ) has been described in patients receiving bisphosphonate therapy and to date several aetiological theories have been proposed, including inhibition of bone remodelling, effect on soft tissues, and the antiangiogenic effect of bisphosphonates. However, almost all cases to date have been described in cancer patients on high-dose intravenous formulations and are often associated with dental procedures. The European Medicines Agency in a recent review concluded that the risk of ONJ is higher in those patients receiving intravenous bisphosphonates for cancer than for patients receiving oral therapy [36] .
Hormone replacement therapy
Numerous randomised placebo-controlled studies including the Womens Health Initiative (WHI) [37] and the Postmenopausal Eestrogen/Progesterone Interventions (PEPI) [38] have established that the postmenopausal decrease in BMD is attenuated by oestrogen, resulting in a lower risk of fracture. However, data from the WHI also suggested that oestrogen/progesterone therapy increases the incidence of breast cancer, coronary heart disease, stroke and venous thromboembolism. Unopposed oestrogen therapy has been shown to increase stroke and thromboembolism only. Therefore, as the overall health risks exceed the benefits, hormone replacement is not considered first-line therapy in the management of postmenopausal osteoporosis.
Selective oestrogen receptor modulators
Raloxifene, lasofoxifene and bazedoxifene are currently the selective estrogen receptor modulators (SERMs) available for use in the treatment of osteoporosis and their effects on vertebral and non-vertebral fractures have been studied in numerous trials reporting beneficial results. The first SERM used to treat osteoporosis, raloxifene, demonstrated a reduced risk of vertebral fractures (HR 0.7), but not nonvertebral fracture in a large 3-year study of postmenopausal women [39] . However, subsequent post hoc analyses reported a decrease in new vertebral and non-vertebral fracture risk in the subgroup of women with severe vertebral fractures at baseline [40] . Bazedoxifene significantly reduced the risk of new vertebral fracture in postmenopausal women with osteoporosis and decreased the risk of non-vertebral fracture in subjects at a higher risk of fracture [41] and in the recent PEARL study of postmenopausal women with osteoporosis, lasofoxifene was associated with reduced risk of both non-vertebral and vertebral fractures [42] . Although SERMs have demonstrated benefits with regard to ER-positive breast cancer, coronary heart disease, and stroke, the main concern with treatment is the three-fold increased risk of venous thromboembolism. Ospemifene and arzoxifene are the new SERM molecules currently under investigation [43, 44] .
Anabolic therapy: parathyroid hormone
Recombinant parathyroid hormone (PTH) 1-34 and 1-84 are anabolic agents that work by stimulating preosteoblasts to mature into bone-forming osteoblasts. When given at low dose by daily subcutaneous injection they enhance bone remodelling. Bone formation begins within the first month of treatment and bone resorption begins after 6 months [45] . Therefore, during the first year of treatment bone remodelling is in a positive balance. In the Fracture Prevention Trial, postmenopausal women with previous vertebral fracture were randomised to PTH (20 or 40 mcg) or placebo. BMD in the 20 mcg and 40 mcg groups increased both at the lumbar spine (9% and 13% respectively) and at the femoral neck (3% and 6% respectively). However, overall fracture risk reduction was proportionately greater and found to be very similar for both dosage groups. In the 20 mcg group, where side effects were less common, the respective relative risks of vertebral and nonvertebral fractures were 0.35 and 0.47. Subgroup analysis showed that the benefits were independent of age, baseline BMD and prevalent vertebral fractures.
The changes in BMD seen with PTH are early and of greater magnitude than those seen with other treatments and it therefore plays a role in the treatment of patients with severe established disease who are at particularly high risk of fragility fractures; T score≤−3.5 without fracture or T score≤−2.5 with fragility fracture. However, the strongest evidence to date in support of the efficacy of PTH in reducing vertebral and non-vertebral fractures showed that its use is likely to be most effective in patients with preexisting fragility fractures and not necessarily associated with very low BMD score [46] .
The main concern with long-term treatment is the development of osteosarcoma, as this was seen in rat models with high-dose treatment [47] . Fortunately, in practice, this has not been observed and very few longterm side effects have been reported. Because of concern regarding long-term safety and plateau in bone formation with treatment beyond 18 months, treatment is limited to a low dose for a maximum of 2 years. PTH is not usually considered first-line therapy owing to cost, the route of administration and the paucity of strong data on nonvertebral fracture reduction. It plays a role, though, in patients with severe disease and when other therapies are not tolerated or have failed. Anti-resorptives should, however, be re-introduced following discontinuation of PTH to preserve the BMD gained on treatment, as demonstrated in an extension of the PaTH study [48] .
Dual action-anti-resorptive and anabolic: strontium ranelate Strontium ranelate has a unique mode of action: it dissociates bone remodelling by reducing bone resorption while allowing continued bone formation. Its effect on vertebral fractures was assessed in SOTI, a trial in which postmenopausal women received daily strontium ranelate or placebo for 3 years [49] . A relative risk reduction in vertebral fractures was seen in favour of strontium; 49% after 1 year and 41% over 3 years (RR 0.59). Strontium ranelate increased bone mineral density at month 36 by 14.4% at the lumbar spine and 8.3% at the femoral neck (P<0.001 for both). Efficacy was subsequently assessed in the prevention of non-vertebral fractures in TROPOS, a double-blind 5-year study of 5,091 postmenopausal women [50] . Relative risk of major fragility fractures was reduced in the strontium group by 19% compared with the placebo group. On extension of these studies to 8 years, BMD of the lumbar spine, femoral neck and total hip continued to increase, with some evidence of sustained anti-fracture efficacy, and strontium was found to be safe and well tolerated [51] .
Women ≥ 80 years are at a higher relative risk of vertebral and non-vertebral fractures and subgroup analysis of these studies concluded an early and sustained reduction of both vertebral and non-vertebral fractures with strontium in these patients [52] . Caution has been advised when interpreting BMD values when on strontium as a proportion of the change in value may be due to accumulation of strontium in the bone tissue; however, an increase in femoral neck BMD has been shown to be associated with a proportional reduction in vertebral fracture incidence [53] . Side effects include transient nausea, diarrhoea and headache. A slight excess of venous thromboembolism (VTE) in patients with a history of thromboembolism has been noted in some but not all trials. A recent large retrospective cohort study reported a greater association of VTE in osteoporotic compared with non-osteoporotic patients (RR 1.75; CI 1.09 to 1.84), but no increased incidence in those treated with strontium compared with alendronate [54] .
Novel therapeutic agents for the management of osteoporosis
Denosumab Denosumab (AMG 162) is a human monoclonal antibody with a high affinity and specificity for receptor activator of NF-kB ligand (RANKL), a key mediator of osteoclastic bone resorption. By reducing RANKL binding to the osteoclast receptor RANK, there is a decrease in differentiation, activity, and survival of osteoclasts, lowering the rate of bone resorption [55] . In a dose-ranging study the efficacy and safety of subcutaneously administered denosumab were evaluated in 412 postmenopausal women (mean age 62 years) with low BMD [56] . Patients were randomised to receive denosumab or alendronate. Denosumab resulted in an increase in BMD from baseline at the lumbar spine of up to 6.7% (vs 4.6% with alendronate) and at the total hip of up to 3.6% (vs 2.1% with alendronate). This study was extended to 24 months and a sustained increase in BMD at total hip, lumbar spine and distal radius was recorded with no increase in adverse events [57] . The effects on bone turnover were found to be fully reversible on discontinuation of the drug, but restored with subsequent treatment [58] . A further larger study of 1,189 postmenopausal women randomised to denosumab 60 mg 6-monthly or alendronate 70 mg weekly showed a significant increase in BMD at all measured skeletal sites in patients on denosumab at 12 months (3.5% vs 2.6%, p<0.0001). There was a significantly greater reduction of bone turnover markers and the safety profile was similar for both treatments [59] .
The FREEDOM trial of 7,868 women aged 60 to 90 years with osteoporosis (BMD T score between −2.5 and −4.0) at the lumbar spine or total hip showed very promising results [60] . Subjects were assigned to receive either 60 mg of denosumab or placebo subcutaneously every 6 months for 36 months. Denosumab reduced the risk of new radiographic vertebral fracture by 68% and reduced the risk of hip fracture by 40%. It also reduced the risk of nonvertebral fracture by 20%. Adverse events were similar to placebo indicating a favourable safety profile. In this large study there was no increase in the risk of cancer, infection, cardiovascular disease, delayed fracture healing or hypocalcaemia and no adverse reactions to the injection of denosumab. Since the publication of this study, suspected cases of ONJ have been described in patients on denosumab [61, 62] , but to date these case reports remain very limited. Significantly greater treatment adherence was observed for subcutaneous administration of denosumab every 6 months than for oral alendronate once weekly [63] with a risk ratio for non-adherence at 12 months of 0.58 (p = 0.043) for denosumab compared with alendronate. Patient preference and satisfaction were also significantly greater for denosumab. The FDA (Food and Drug Administration of the USA) and EMEA (European Medicines Agency) have approved denosumab for the treatment of postmenopausal osteoporosis and it is currently available for use in clinical practice.
Odanacatib
Cathepsin K is a lysosomal cysteine protease expressed in abundance by osteoclasts that degrades Type I collagen and is responsible for degradation of the organic bone matrix during bone remodelling. Odanacatib (MK-822) is a potent and selective inhibitor of Cathepsin K [64] and has been shown in studies to reduce osteoclast-mediated bone resorption. In two double-blind, randomised, placebocontrolled studies, postmenopausal women received odanacatib 2.5 mg once weekly for 3 weeks or once daily for 21 days. It was well tolerated and had a long half-life (t ½ 66-93 h) consistent with once-weekly dosing. A reduction in biochemical markers of bone resorption of up to 81% was seen [65] . A recent study of 399 women with BMD Tscores between −2.0 and −3.5 at the lumbar spine or femoral neck was performed whereby participants were randomly assigned to receive placebo or one of four doses of odanacatib (3, 10, 25 or 50 mg weekly) over 24 months. After 24 months, lumbar spine and total hip BMD increased 5.5% and 3.2% respectively in patients on 50 mg odanacatib compared with placebo [66] . Unlike other, less selective cathepsin inhibitors, which caused skin reactions, the safety and tolerability of odanacatib are similar to placebo. Results of ongoing large scale trials to evaluate the effects of odanacatib on fracture risk in postmenopausal women are awaited.
Glucagon-like peptide 2
There is a circadian pattern to bone remodelling, as shown by biochemical assessments, whereby bone resorption is reduced during the daytime and increased at night, and this pattern has been linked to food intake. GLP-2 is released in the small intestine almost immediately after food intake and its secretion is therefore reduced overnight with nocturnal fasting. The presence of GLP-2 receptors in osteoclasts suggests that GLP-2 may form part of an "entero-osseous axis", coordinating nutrient-dependent bone turnover. As bone resorption occurs at an increased rate during this fasting period it was hypothesised that administration of GLP-2 at bedtime may reduce this rate of bone resorption overnight. A double-blind placebo-controlled trial of 60 postmenopausal women administered GLP-2 daily for 14 days showed a significant and sustained reduction in bone resorption (Ctx) with the added advantage of not decreasing bone formation (OC), unlike other antiresorptive agents. [67] . The investigators then extended the study period to 4 months. This phase II, placebo-controlled trial of 160 postmenopausal women treated with GLP-2 (3 doses) over 120 days similarly resulted in a reduction in the nocturnal rise of C-telopeptide and no effect on osteocalcin and an increase in hip BMD (1.1% with highest dose of 3.2 mg, p=0.007) [68] . The overall rates of adverse events in the treatment groups were similar and there were no signs of tachyphylaxis or antibody production against GLP-2. The results indicate that GLP-2 produces a substantial decrease in bone resorption without suppression of bone formation, thereby changing the bone remodelling balance in favour of bone formation, particularly at the hip. If this disassociation between bone resorption and formation can be sustained with no adverse effects, it may prove an interesting future therapy for osteoporosis. Studies are also currently underway looking at GLP-1 as a possible anabolic agent to improve deficiencies in bone formation associated with glucose intolerance.
Wnt signalling: inhibitors of sclerostin and Dickkopf 1 Wnt proteins are a large family of extracellular glycoproteins involved in many cellular processes. The Wnt/betacatenin signalling pathway has emerged as a key regulator of bone homeostasis and recently neutralising inhibitors have emerged as a possible therapeutic option for the management of osteoporosis [69] . These include antibodies to Sclerostin and Dkk-1 and also inhibitors of secreted Frizzled-related protein 1 and glycogen synthase kinase 3beta. Sclerostin is secreted by osteocytes and genetic studies have shown that it is a key negative regulator of bone formation. Its inhibition was assessed using a cell culture model of bone formation to identify a sclerostinneutralising monoclonal antibody (Scl-AbII) [70] . When ovariectomised rats were administered Scl-Abll for 5 weeks robust anabolic effects were noted on trabecular, periosteal, endocortical, and intracortical surfaces. It resulted in complete reversal of bone loss at several skeletal sites, but also further increased bone mass and bone strength to levels greater than those found in control rats. In the first human study a single subcutaneous dose of Scl-AbII (AMG 785) was administered to 72 healthy men and postmenopausal women. It resulted in an increase in P1NP and osteocalcin and a dose-related decrease in the bone marker CTx at day 84 of treatment. An increase of 5.3% in BMD was seen at the lumbar spine and of 2.8% at the total hip. Neutralising antibodies developed in 2 patients, but had no effect on the pharmacokinetics of this agent [71] . Dkk-1 is a negative regulator of bone homeostasis and levels are significantly higher in osteoporotic women compared with controls [72] . Manipulation of its function and expression has therapeutic significance for the treatment of osteoporosis and progressive Dkk-1 reduction has been shown to increase trabecular and cortical bone mass in mice and primates [73, 74] . Human studies showing beneficial effects are currently underway.
Calcium sensing receptor, activin receptor fusion protein and integrin aub3
Potential future targets for osteoporosis include calcium sensing receptor, activin receptor fusion protein and integrin aub3. Antagonists to calcium sensing receptor result in transient PTH surge with each oral dose similar to that seen with intermittently administered exogenous PTH. Activin, a cofactor for osteoclastogenesis, binds to activin receptor IIA and an antibody to it has shown a reduction in C-telopeptide in postmenopausal women. Antibodies to alpha(v)beta(3) integrin, expressed on osteoclasts, inhibit bone resorption in vitro and in vivo, suggesting an important role in regulating osteoclast function. Although interesting novel targets, future studies will determine longterm tolerability and safety. It is likely to be some years before these agents are introduced to clinical practice.
Prescribing considerations
Osteoporosis is predominantly a disease of older adults so, when prescribing, other factors such as cognition, compliance, co-morbidities and route of administration must be taken into consideration. Medication effectiveness needs to be balanced against tolerability in individual patients. All patients should be on calcium supplementation and should be vitamin D replete. For the well, compliant older person, with no contra-indications, oral weekly bisphosphonate therapy or oral daily strontium are considered first line. However, hip fracture is the main concern amongst older patients with osteoporosis and bisphosphonates have welldocumented hip fracture risk reduction, which is maintained over many years.
Repletion of vitamin D is particularly important in the frailest older patients, such as nursing home residents or older patients with poor mobility and limited sunlight exposure. It may be given intramuscularly if compliance is uncertain [75] . It also suppresses parathyroid hormone, increases bone mineral density and reduces falls [76] and hip fracture.
In patients who have difficulty swallowing medications or in those intolerant of oral bisphosphonates due to upper gastrointestinal disturbance, annual intravenous zoledronic acid or subcutaneous denosumab are useful options. It should also be considered when compliance with oral therapy remains an issue in community-dwelling patients.
More than half of all fractures in the community occur in patients with osteopenia. However, most studies assessing antifracture efficacy of drugs include osteoporotic patients who are at higher absolute risk of fracture. In cases of osteopenia, treatment with strontium can be considered. Pooled data from SOTI and TROPOS reported significant antifracture efficacy of strontium ranelate in women with lumbar spine (LS) and femoral neck (FN) osteopenia [77] . The risk of clinical vertebral fractures was reduced by 60% with alendronate in a subgroup of patients from the FIT 1 study with FN osteopenia and prevalent fractures [78] . Further studies are needed to determine effective therapies to reduce hip fracture risk in patients with osteopenia.
Parathyroid hormone is recommended as an alternative treatment to bisphosphonates or strontium in the setting of a contraindication, intolerance to or failure of these drugs. Despite PTH's known efficacy, due to its high cost and without very strong evidence to support superiority to other treatments in antifracture efficacy, its use is likely to remain relatively restricted.
Osteoporosis in older persons often co-exists with chronic kidney disease (CKD) and could be included in the broad spectrum of metabolic bone conditions that accompany a decline in renal function. As the population prevalence of CKD is increasing, the management of osteoporosis in these patients is a frequently encountered problem. In advanced stages of CKD it is important to discriminate between osteoporosis and other forms of renal osteodystrophy, which can also impair bone strength and lead to fracture. WHO criteria for diagnosing osteoporosis can be applied in CKD stages 1 to 3, once biochemical profiling is normal. In these cases current registered therapies for osteoporosis have proven safety and can be used. In the setting of fragility fractures in more advanced stages of kidney disease the diagnosis and management of osteoporosis is less clear. Careful assessment of bone turnover using serum levels of parathyroid hormone and bone-specific alkaline phosphatase is needed. In some cases, double-tetracycline labelled bone biopsy may be indicated to rule out adynamic bone disease before considering anti-resorptive treatment. In fracture patients with osteoporosis and stages 4 and 5 CKD treatment is difficult as therapies remain unlicensed in this setting. However, post hoc analyses of trials using risedronate, alendronate and raloxifene have reported the tolerability of these drugs in stage 4 CKD [79] [80] [81] . No efficacy data, however, support their use in end-stage kidney disease. If recurrent fragility fractures pose a great risk to these patients it may be reasonable, based on known pharmacokinetics, to reduce the dose of bisphosphonate by half after clear diagnosis is made and consent from the patient is sought. In patients with renal osteodystrophy on dialysis, ibandronate has shown a significant increase in BMD and decrease in BTM [82] . Alendronate has also shown a bonepreserving effect in patients on haemodialysis [83] . In all patients with advanced CKD supplementation with active vitamin D is essential to reduce the effects of secondary hyperparathyroidism. In summary no consensus exists to guide our treatment decisions in cases of osteoporosis in stages 4 and 5 CKD and further large-scale prospective studies are needed. As denosumab is a monoclonal antibody, it is not cleared by the kidneys, which makes it a safer option for people who have renal disease. In patients with varying degrees of renal function, including patients on dialysis, the degree of renal impairment had no effect on the pharmacokinetics of denosumab. Therefore, no dose adjustments of this drug are required with different degrees of renal impairment.
Conclusion
The incidence of osteoporosis-related fractures will rise substantially over the coming decades as the population ages. This increased incidence will have significant social and economic implications for most countries, particularly in the developed world. In recent years our understanding of normal bone physiology and the mechanisms underlying the development of osteoporosis has significantly advanced and this has led to the development of new therapies. Currently, we have good anti-fracture data to support the use of many available anti-resorptive and anabolic drugs and supplementation of calcium and vitamin D. Newer agents, particularly denosumab, will increase the therapeutic options for clinicians in the coming years. Determination of future fracture risk, evaluation of co-morbidities, measurement of renal function and estimation of potential compliance difficulties are all important considerations for the prescribing physician to take into account when deciding upon which agents to use in individual patients. 
